SG10201503157PA - Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation - Google Patents

Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation

Info

Publication number
SG10201503157PA
SG10201503157PA SG10201503157PA SG10201503157PA SG10201503157PA SG 10201503157P A SG10201503157P A SG 10201503157PA SG 10201503157P A SG10201503157P A SG 10201503157PA SG 10201503157P A SG10201503157P A SG 10201503157PA SG 10201503157P A SG10201503157P A SG 10201503157PA
Authority
SG
Singapore
Prior art keywords
sphingosine
receptor modulators
phosphate receptor
muscle inflammation
treat muscle
Prior art date
Application number
SG10201503157PA
Inventor
Syed Sohail Ahmed
Marco Londei
Timothy Wright
Peter Gergely
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201503157P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG10201503157PA publication Critical patent/SG10201503157PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG10201503157PA 2008-07-23 2009-07-22 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation SG10201503157PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161005 2008-07-23

Publications (1)

Publication Number Publication Date
SG10201503157PA true SG10201503157PA (en) 2015-06-29

Family

ID=40090418

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201503157PA SG10201503157PA (en) 2008-07-23 2009-07-22 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation

Country Status (25)

Country Link
US (2) US9149459B2 (en)
EP (2) EP2307007B1 (en)
JP (2) JP5878015B2 (en)
KR (2) KR101624098B1 (en)
CN (1) CN102105144B (en)
AU (1) AU2009273259B2 (en)
BR (1) BRPI0916232A2 (en)
CA (1) CA2730751A1 (en)
CL (1) CL2011000138A1 (en)
CY (1) CY1115662T1 (en)
DK (1) DK2307007T3 (en)
ES (1) ES2522345T3 (en)
HK (1) HK1155096A1 (en)
HR (1) HRP20141152T1 (en)
IL (2) IL210550A (en)
MA (1) MA32557B1 (en)
MX (1) MX2011000881A (en)
NZ (1) NZ590328A (en)
PL (1) PL2307007T3 (en)
PT (1) PT2307007E (en)
RU (1) RU2521286C2 (en)
SG (1) SG10201503157PA (en)
SI (1) SI2307007T1 (en)
WO (1) WO2010010127A1 (en)
ZA (1) ZA201100166B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186473B (en) 2008-08-18 2014-07-02 诺华股份有限公司 Compounds for the treatment of peripheral neuropathies
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
FR3000959B1 (en) 2013-01-14 2015-08-21 Holis Technologies NOVEL SYNTHETIC INTERMEDIATES FOR ACCEDING WITH GOOD YIELDS TO SPHINGOSINE, CERAMIDE AND SPHINGOMYELIN DERIVATIVES
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11061017B2 (en) 2015-06-18 2021-07-13 Cytoo High throughput and functional screening method for muscle related disorders and biological processes
US20190047951A1 (en) 2016-01-04 2019-02-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CN115884762A (en) * 2020-08-20 2023-03-31 南京明德新药研发有限公司 Acetophenone oxime compound and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507016A (en) 1994-03-10 1997-09-09 Bayer Ag Oxime derivatives
AR035411A1 (en) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co USE OF A TACROLIMUS DERIVATIVE TO MANUFACTURE A NEUROTROPHIC AGENT, COMPOSITIONS AND MANUFACTURING ITEMS OR KITS THAT UNDERSTAND IT, METHOD FOR MANUFACTURING AN AGENT THAT UNDERSTANDS AND FABRICS AND GRAINTS WITH A NERVOUS CELL TREATED WITH THIS COMPOSITE
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
ATE441654T1 (en) * 2002-01-18 2009-09-15 Merck & Co Inc EDG RECEPTOR AGONISTS
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
JP4575920B2 (en) * 2003-05-19 2010-11-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Immunosuppressive compounds and compositions
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ATE391710T1 (en) * 2004-02-16 2008-04-15 Esteve Labor Dr SUBSTITUTED AZETIDINE COMPOUNDS AS CYCLOOXIGENASE-1-CYCLOOXYGENASE-2 INHIBITORS AND THEIR PREPARATION AND USE AS A MEDICATION
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
EP1804793A4 (en) * 2004-10-22 2010-03-31 Merck Sharp & Dohme 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
MX2007006373A (en) 2004-11-29 2007-06-20 Novartis Ag Dosage regimen of an s1p receptor agonist.
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
BRPI0715950A2 (en) * 2006-08-17 2013-07-30 Univ Chicago treatment of inflammatory diseases
US8044076B2 (en) * 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Compounds
US8324254B2 (en) 2007-04-19 2012-12-04 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
TW200920355A (en) 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
PT2379069E (en) * 2008-12-22 2015-07-03 Novartis Ag Dosage regimen of an s1p receptor agonist

Also Published As

Publication number Publication date
RU2011106356A (en) 2012-08-27
IL210550A0 (en) 2011-03-31
AU2009273259B2 (en) 2013-05-02
BRPI0916232A2 (en) 2017-08-29
WO2010010127A1 (en) 2010-01-28
PL2307007T3 (en) 2015-03-31
RU2521286C2 (en) 2014-06-27
DK2307007T3 (en) 2014-11-10
NZ590328A (en) 2013-04-26
US20110124620A1 (en) 2011-05-26
KR101624098B1 (en) 2016-05-24
JP2015038100A (en) 2015-02-26
EP2695615A2 (en) 2014-02-12
PT2307007E (en) 2014-11-13
AU2009273259A1 (en) 2010-01-28
MX2011000881A (en) 2011-03-02
ES2522345T3 (en) 2014-11-14
EP2307007A1 (en) 2011-04-13
SI2307007T1 (en) 2014-11-28
CY1115662T1 (en) 2017-01-25
CA2730751A1 (en) 2010-01-28
KR101608108B1 (en) 2016-03-31
US9149459B2 (en) 2015-10-06
JP2011528695A (en) 2011-11-24
CL2011000138A1 (en) 2011-07-01
KR20110031996A (en) 2011-03-29
CN102105144A (en) 2011-06-22
ZA201100166B (en) 2011-09-28
IL243612A0 (en) 2016-02-29
KR20160039694A (en) 2016-04-11
EP2695615A3 (en) 2014-04-30
HK1155096A1 (en) 2012-05-11
JP5878015B2 (en) 2016-03-08
US20160175282A1 (en) 2016-06-23
HRP20141152T1 (en) 2015-01-16
IL210550A (en) 2016-02-29
EP2307007B1 (en) 2014-08-27
CN102105144B (en) 2013-11-13
MA32557B1 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
IL243612A0 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
HUS2000038I1 (en) Novel modulators of sphingosine phosphate receptors
HUS2000045I1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2344484A4 (en) S1p receptors modulators and their use thereof
HK1215281A1 (en) Brown adipocyte progenitors in human skeletal muscle
IL219690A0 (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2349321A4 (en) Annexin and its use to treat inflammatory disorders
SI2137141T1 (en) Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
IL209306A0 (en) Novel modulators of sphingosine phosphate receptors
IL207965A0 (en) N-substitutedbenzenepropanamide ofr denzenepropenamide derivatives for use in the treatment of pain and inflammation
GB2464927B (en) Apparatus and method for metering the use of electricity
EP2300044A4 (en) Methods and compositions for the management of pain using omega-conotoxins
TWI340035B (en) Lemnalol applying for treating inflammation and pain